Targeting the IL-6/STAT3 Signalling Cascade to Reverse Tamoxifen Resistance in Estrogen Receptor Positive Breast Cancer

Breast cancer is the most common female cancer. About 70% of breast cancer patients are estrogen receptor α (ERα) positive (ER+) with tamoxifen being the most commonly used anti-endocrine therapy. However, up to 50% of patients who receive tamoxifen suffer recurrence. We previously identified BQ3236...

Full description

Bibliographic Details
Main Authors: Ho Tsoi, Ellen P. S. Man, Ka Man Chau, Ui-Soon Khoo
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Cancers
Subjects:
Online Access:https://www.mdpi.com/2072-6694/13/7/1511